Telisotuzumab vedotin
- Generic Name
- Telisotuzumab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1714088-51-3
- Unique Ingredient Identifier
- 976X9VXC3Z
- Background
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06568939
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06093503
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT05513703
- Locations
- 🇫🇷
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267, Bron, Rhone, France
🇦🇺Monash Medical Centre /ID# 247679, Clayton, Victoria, Australia
🇫🇷CHU Lille - Hôpital Albert Calmette /ID# 246263, Lille, Hauts-de-France, France
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 698
- Registration Number
- NCT04928846
- Locations
- 🇿🇦
Steve Biko Academic Hospital /ID# 230883, Pretoria, Gauteng, South Africa
🇺🇸University of Alabama at Birmingham - Main /ID# 247074, Birmingham, Alabama, United States
🇺🇸Ironwood Cancer & Res Ctr /ID# 262446, Chandler, Arizona, United States
Expanded Access to Telisotuzumab Vedotin
- Conditions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04830202
- Locations
- 🇺🇸
Oncology & Hematology Specialist /ID# 248083, Mountain Lakes, New Jersey, United States
🇺🇸Sutter Medical Group /ID# 254816, Sacramento, California, United States
🇦🇺Western Heamatology and Oncology Clinics /ID# 243364, West Perth, Western Australia, Australia
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT03539536
- Locations
- 🇺🇸
Veterans Healthcare System /ID# 215602, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 237
- Registration Number
- NCT02099058
- Locations
- 🇺🇸
University of California, Los Angeles /ID# 148295, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital /ID# 129804, Boston, Massachusetts, United States
🇺🇸Duke Cancer Center /ID# 123763, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.